Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
Mark to market on Ranbaxy
Description
Ranbaxy Laboratories got approval to launch Lipitor in the December quarter. But Mint?s Ravi Ananthanarayanan says that while consolidated revenues rose, it has disappointed investors by paying more than expected to Teva Pharmaceutical.
More from User
06:52
Jet Airways crisis: Who is to blame, lending banks or promoter Naresh Goyal?
Mint
01:38
What to expect from Reliance Q4 earnings?
Mint
29:58
Zia Mody on adversarial deal making, fear of missing out in private equity
Mint
19:20
Apex Court squashes RBI's Feb 12 Circular on Stressed Assets Resolution : A Decode
Mint
12:50
Marico Founder Harsh Mariwala on how Indian start-ups can scale up & thrive
Mint
23:10
'Hostile' takeovers: L&T-Mindtree saga signals new era in Indian M&A deals?
Mint